<DOC>
	<DOCNO>NCT01177852</DOCNO>
	<brief_summary>Multicenter clinical trial , phase III , control active medicine , open , randomize , enroll 962 child , 2 12 year old , suffer acute inflammation upper airway characterize non-productive cough , daytime/nighttime , duration least 3 5 consecutive day ( without systemic/topic use medication period ) follow nasal congestion , without associate nasal symptom ( sneeze , runny nose , nasal itch and/or mouth breathing ) . The subject allocate 2 parallel group , receive medicine study , accord randomization .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Control Cough Relief Nasal Symptoms Children 2-12 Years Old , Suffering From Cough Acute Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Dipropizine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Brompheniramine</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>1 . Patients 2 12 year old , sex ; 2 . Clinical condition compatible acute rhinitis accompany nasal obstruction ; 3 . Nonproductive cough , daytime and/or nighttime least 3 5 consecutive day duration ; 4 . Score great equal 3 point cough severity score ( As per item 4.1.2 ) ; 5 . Score great equal 2 point nasal obstruction severity score ( As per item 4.1.3 ) ; 6 . ICF sign parent/caregiver/representant ; 7 . Parent/Caregiver/Representant capacity , accord investigator evaluation , compliance treatment protocol requirement , fulfil regular visit ; 1 . Nonproductive cough purulent smear , fever ( axillar temperature superior 37,8°C/100°F ) , purulent runny nose sign symptom bacteria infection upper low airway 7 day screening/randomization visit ; 2 . Septal deviation level III ( region nasal cavity ) and/or nasal polyps determinant condition nasal congestion ; 3 . Previous diagnosis asthma ; 4 . Patients treatment chronic allergy ; 5 . Presence purulent mucopurulent secretion , nasal vault mal formation ( cleft lip cleave nasolabial correct ) nasal vestibule ; 6 . Current use systemic antibiotic reason ; 7 . Use prohibit medicine within prescribed period V0 show item 9.3 protocol ; 8 . Participation last one year clinical protocol ; 9 . Any psychiatric disease , include major depression ; 10 . Presence mental retardation cause ; 11 . Diagnosis renal hepatic failure ; 12 . History hypersensitivity component study drug ; 13 . Relatives sponsor´s study site´s employee ; 14 . Current evidence clinically significant disease : hematopoietic , gastrointestinal , cardiovascular , hepatic , renal , neurological , endocrine , psychiatric , autoimmune , pulmonary , another disease block patient participation ; 15 . Patient parent/caregiver/representant history lack compliance treatment previous treatment protocol ; 16 . Any finding clinical observation ( anamnesis physical exam ) laboratory abnormality ( eg , blood glucose , blood count ) , disease ( example , liver , cardiovascular system , lung ) therapy , opinion investigator , may endanger patient interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cough , acute rhinitis , common cold , nasal symptom , child .</keyword>
	<keyword>Acute inflammation upper airway</keyword>
</DOC>